|
Exhibit 99.46
CORD BLOOD AMERICA SIGNS CONSULTING AGREEMENT WITH MIDTOWN
PARTNERS & CO., LLC TO EVALUATE STRATEGIC ALTERNATIVES TO
UNLOCK VALUE IN ITS SUBSIDIARIES.
LOS
ANGELES, CA. June __, 2007 - Cord Blood America, Inc. (OTC Bulletin
Board: CBAI), the umbilical cord blood stem cell preservation
company ( http://www.cordblood-america.com ) focused on
bringing the life saving potential of stem cells to families
nationwide and internationally, today announced that it has signed
a consulting agreement with Midtown Partners & Co., LLC, to
evaluate strategic alternatives to unlock value for its
subsidiaries.
“Cord Blood America is seeking to unlock value to its
shareholders for its Philadelphia, Pa., based CorCell subsidiary,
among others, because of its significant potential stand alone
value,” said Matthew Schissler, Cord Blood America Chairman
and CEO. “We have sought out the expertise of Midtown
Partners, with vast experience in this sector, and Cord Blood
America has contracted with them to lead the search and evaluation
process for CorCell.”
Richard
Kreger, Senior Vice President, Midtown Partners, said that
“Cord Blood America is a valuable property that deserves the
attention of the public markets. The stem cell sector is
trading at significantly higher multiples to revenue than Cord
Blood America. Cord Blood America has some of the best
financial numbers in the sector, yet has not achieved the name
recognition deserved in the stem cell arena. We want to
improve the street perception of the company and do it quickly by
identifying the best strategic alternatives for the company and its
subsidiaries.”
“Management sees this opportunity as a significant step
forward in Cord Blood America’s overall business plan.
Management has worked diligently to line up this milestone
opportunity , which could entirely
fund the parent company’s future growth,” Mr. Schissler
said.
"This
capital releasing transaction will be
|
